About this speaker
Philip Ashton-Rickardt gained his PhD in Molecular Immunology with Sir Kenneth Murray FRS at the University of Edinburgh. After postdoctoral training at the Massachusetts Institute of Technology he embarked on life as an academic immunologist holding professorships at the University of Chicago and Imperial College London. He made the transition to industry in 2017 when he returned to Boston to start Smith Therapeutics, which developed engineered T lymphocytes to treat neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease. Philip developed and brokered the acquisition of Smith Therapeutics technology to clinical stage companies. He then joined Sigilon Therapeutics as Chief Scientific Officer in 2021, where he provides strategic leadership and oversight for R&D activities towards the development of shielded-living cell products that treat rare, immunological and neurodegenerative diseases.
